An official website of the United States government
Home
Name
avutometinib/defactinib
Alternate Names
Avmapki Fakzynja Co-pack
Abbreviations
None
Category
Chemotherapy
Subcategory
Kinase inhibitor
NSC Number
None
Primary Site
Histology
low grade serous ovarian cancer
Remarks
On May 8, 2025, the FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
Coding
This drug should be coded
